Clinical Trials Logo

Brain Neoplasms clinical trials

View clinical trials related to Brain Neoplasms.

Filter by:

NCT ID: NCT05538130 Recruiting - Colorectal Cancer Clinical Trials

A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors

Start date: November 30, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times per day, but this could change to once daily or another frequency). Depending on the part of the study, participants may also receive another study medicine. - In the first part of the study, people with melanoma or other solid tumors may also receive encorafenib. Encorafenib comes as a capsule and is taken once per day. - In the second part of the study, people with melanoma or other cancers with abnormalities in a gene called "BRAF" will receive PF-07799544 with other study medicines (for example, PF-07799933). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

NCT ID: NCT05535413 Recruiting - Brain Metastases Clinical Trials

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, multicenter, open-labeled clinical study of UTD1 combined with Capecitabine in metastatic HER2-negative breast cancaner patients with brain metastases. This study aims to evaluate the efficacy and safety of UDT1 combined with capecitabine in metastatic HER2-negative breast cancer patients with brain metastases.

NCT ID: NCT05522660 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

USZ-STRIKE
Start date: November 30, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymptomatic brain metastases from melanoma or NSCLC. This proposed randomised phase III clinical study addresses one of the most controversial issues in the current approach to patients with brain mets: the timing of SRS in patients eligible for systemic immune checkpoint inhibition or targeted therapy in order to guide therapeutic options as to what strategy allows the best compromise between best survival and best QoL.

NCT ID: NCT05521984 Recruiting - Clinical trials for Pediatric Brain Tumor

Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Start date: April 3, 2023
Phase: Phase 1
Study type: Interventional

This is a longitudinal, dose-finding, open label safety and tolerability phase Ib treatment study. The study hypothesis is that dapagliflozin will be well-tolerated by brain tumor patients on chemotherapy as assessed by tolerability and side effect profiles.

NCT ID: NCT05503251 Recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases

Start date: August 30, 2022
Phase: N/A
Study type: Interventional

This phase II trial studies the effect of neuropsychological evaluation and intervention in maintaining quality of life after radiation therapy in patients with cancer that has spread to the brain (metastases). Quality of life refers to the overall enjoyment of life. It holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness. Neuropsychological evaluation is used to examine the cognitive (thinking) consequences of brain damage, brain disease, and severe mental illness. Deterioration of both quality of life and cognitive function is common when receiving radiation to the brain. Neuropsychological evaluation with a certified neuropsychologist may improve quality of life or cognitive function after radiation therapy.

NCT ID: NCT05484245 Recruiting - Clinical trials for Arteriovenous Malformations

Sonography-guided Resection of Brain Mass Lesions

SOMALI
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Objective of the study is to determine possibilities of intraoperative sonography in detecting of various brain mass lesions, assessing extent of their resection and define indications to use ultrasound-guided needle or ultrasound wire-guided port.

NCT ID: NCT05484219 Recruiting - Clinical trials for Arteriovenous Malformations

Functional Navigation in Surgery of Cerebral Tumors and Vascular Malformations

FUN
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to assess accuracy, advantages of functional neuronavigation and calculate safe distance from motor areas to brain tumors and vascular malformations in image-guided surgery.

NCT ID: NCT05480644 Recruiting - Clinical trials for Brain Metastases, Adult

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

Start date: December 1, 2022
Phase:
Study type: Observational

The purpose of this protocol is to create a repository of blood samples from patients diagnosed with primary and metastatic brain tumors who are being seen in the Department of Radiation Oncology at Duke Cancer Center.

NCT ID: NCT05477680 Recruiting - Clinical trials for Arteriovenous Malformations

Intraoperative Brain Shift Calculation Study

BRASH
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to calculate magnitude, type of intraoperative brain shift and assess possibility of it's prediction.

NCT ID: NCT05477316 Recruiting - Brain Metastases Clinical Trials

A Study to Assess the Efficacy of Cerebellar IMRT Combined With Cerebral SRS in Patients With Brain Metastases

Start date: February 11, 2021
Phase: N/A
Study type: Interventional

A single-arm pilot study, to assess the efficacy of cerebellar IMRT combined with cerebral SRS in patients with brain metastases that are predominantly in the posterior fossa - a novel treatment approach